Who are Preventative Medication (PM)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cytotec, ketorolac (Acular LS), Postoperative pain management with metamizole, ABS, ASA, Diclofenac oral + scopolamina oral.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/preventative-medication-pm.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Preventative Medication (PM) — Competitive Intelligence Brief

Preventative Medication (PM) (Preventative Medication (PM)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: antiplatelet. Area: Cardiovascular.

marketed antiplatelet COX-1 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Preventative Medication (PM) (Preventative Medication (PM)) — NYU Langone Health. Prevents cardiovascular events by inhibiting platelet aggregation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Preventative Medication (PM) TARGET	Preventative Medication (PM)	NYU Langone Health	marketed	antiplatelet	COX-1
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
ketorolac (Acular LS)	ketorolac (Acular LS)	Center For Excellence In Eye Care	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Postoperative pain management with metamizole	Postoperative pain management with metamizole	Medical University of Silesia	marketed	Non-selective NSAID (nonsteroidal anti-inflammatory drug)	Cyclooxygenase (COX-1 and COX-2)
ABS	ABS	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
ASA	ASA	Biogen	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Diclofenac oral + scopolamina oral	Diclofenac oral + scopolamina oral	Hospital de Clinicas de Porto Alegre	marketed	NSAID + anticholinergic combination	COX-1/COX-2 (diclofenac); muscarinic acetylcholine receptors (scopolamine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (antiplatelet class)

Beijing Tiantan Hospital · 1 drug in this class
Catholic University of the Sacred Heart · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
NYU Langone Health · 1 drug in this class
Samsung Medical Center · 1 drug in this class
Sheba Medical Center · 1 drug in this class
Sichuan Provincial People's Hospital · 1 drug in this class
University of Athens · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Preventative Medication (PM) — Competitive Intelligence Brief. https://druglandscape.com/ci/preventative-medication-pm. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab